Sanofi Multiple Sclerosis Drug Gets EU Approval Despite FDA Letter - Sanofi (NASDAQ:SNY)

Sanofi won European approval for Cenrifki in SPMS and secured Japan authorization for Wayrilz in chronic ITP.

Raccontata dabenzinga.com